Clinical trials: Mini-Mental State Examination
Alzheimer's Disease
A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease
The purpose of this study is to assess the efficacy, safety, and tolerability of Exelon® patch in patients with probable AD (MMSE 10-20), in order to support a planned regulatory submission and registration of Exelon transdermal…
- Trial name
- NCT01399125
- Testing
- Rivastigmine Patch, Rivastigmine Capsules
- Where
- 16 sites in China
- Volunteers
- 501 people
- Sponsor
- Novartis Pharmaceuticals
Dementia With Lewy Bodies
Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies
This study will be conducted to compare Irsenontrine to placebo on the cognitive endpoint of Montreal Cognitive Assessment (MoCA) and the global clinical endpoint of Clinician's Interview Based Impression of Change Plus…
- Trial name
- NCT03467152
- Testing
- Irsenontrine
- Where
- 74 sites in United States, France and 5 more
- Volunteers
- 326 people
- Sponsor
- Eisai Inc.
Alzheimer's Disease, Dementia
Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease
The purpose of this study was to determine the safety and effectiveness of a relatively high dose of galantamine, 32 mg /day in a three-times daily dosage, compared with placebo in treating patients with Alzheimer's disease.
- Trial name
- NCT00338117
- Testing
- Galantamine hydrobromide
- Volunteers
- 554 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Cognitive Decline, Cognitive Dysfunction
Open-label, Post-marketing, Prospective Study to Assess Impact of COVID-19 on Cognitive Function in Patients
The objective of this study is to compare the impact of the coronavirus disease (SARS-CoV-2, or COVID-19) on cognitive function in the population of patients who have been diagnosed, treated and recovered from the COVID-19…
- Conditions
- Cognitive Decline, Cognitive Dysfunction, Brain Health, Post CoV-2 Syndrome
- Trial name
- COVID19 (NCT04950673)
- Testing
- Cognivue
- Where
- 4 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Cognivue, Inc.